MedPath

Study for healthy ageing

Phase 1
Conditions
Healthy ageing, functional decline
Therapeutic area: Not possible to specify
Registration Number
EUCTR2012-001249-41-FR
Lead Sponsor
niversity Hospital of Zurich and City Hospital Waid
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
2152
Inclusion Criteria

- Mini Mental State Examination Score of at least 24
- Living in the community
- Sufficiently mobile to come to the study centre, to walk 10 meters with or without walking aid and to get in and out of a chair without help
- Able to swallow study medication
- Able and willing to participate, sign informed consent (including consent to analyze all samples until withdrawal) and cooperate with study procedures
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 2152

Exclusion Criteria

(1) Consumption of more than 1000 IU vitamin D/day in the 6 month prior to enrolment, and/or a bolus of 300'000 IU vitamin D or more in the 12 month prior to enrolment, and /or unwillingness to limit vitamin D intake to the current standard of 800 IU/day of vitamin D during the course of the trial
(2) Unwillingness to limit calcium supplement dose to 500 mg per day for the duration of the trial
(3) Taking omega-3 fat supplements and unwilling to forgo their use for the duration of the trial
(4) Use of any active vitamin D metabolite (i.e. Rocaltrol,
alphacalcidiol), PTH treatment (i.e. Teriparatide), or Calcitonin at
baseline and unwillingness to forego these treatments during the
course of the trial
(5) Current or recent (previous 4 months) participation in another clinical trial, or plans of such participation in the next 3 years (corresponding to DO-HEALTH length)
(6) Presence of the following diagnosed health conditions in the last 5 years: history of cancer (except non-melanoma skin cancer); myocardial infarction, stroke, transient ischemic attack, angina pectoris, or coronary artery intervention
(7) Severe renal impairment (creatinine clearance = 15 ml/min) or
dialysis, hypercalcaemia (> 2.6 mmol/l)
(8) Hemiplegia or other severe gait impairment
(9) History of hypo- or primary hyper-parathyroidism
(10) Severe liver disease
(11) History of granulomatous diseases (i.e. tubercolosis, sarcoidosis)
(12) Major visual or hearing impairment or other serious illness that would preclude participation
(13) Living with a partner who is enrolled in DO-HEALTH (we exclude couples)
(14) Living in assisted living situations or a nursing home
(15) Temporary exclusion: acute fracture in the last 6 weeks
(16) Epilepsy and/or use of anti-epileptic drugs
(17) Individuals who fell more than 3 times in the last month
(18) Osteodystrophia deformans (M. Paget, Paget's disease)

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath